SCHEMBL3604098

SCHEMBL3604098

[NH]c1cccc2c1NC(=O)C(N1CCC(=O)CC1)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.39
DRD4 P21917 2/20 0.39
CRBN Q96SW2 2/20 0.37
RAB9A P51151 1/20 0.36
CHRNA7 P36544 1/20 0.33
TSHR P16473 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.32
DRD1 P21728 1/20 0.32
DRD5 P21918 1/20 0.32
DRD3 P35462 1/20 0.32
DDB1 Q16531 1/20 0.32
TAAR1 Q96RJ0 1/20 0.31
OPRM1 P35372 3/20 0.31
OPRK1 P41145 3/20 0.31
OPRL1 P41146 3/20 0.31
OPRD1 P41143 2/20 0.31
HTR1A P08908 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3595636 0.88 TSHR (0.46) DRD2DRD4CRBNRAB9ACHRNA7
SCHEMBL3593849 0.86 DRD2 (0.41) DRD2DRD4CRBNRAB9ATSHR
SCHEMBL3599720 0.86 DRD2 (0.39) DRD2DRD4CRBNRAB9ATSHR
SCHEMBL3597119 0.85 ALDH1A1 (0.39) DRD2DRD4CRBNRAB9ATSHR
SCHEMBL3594128 0.85 POLB (0.39) DRD2DRD4CRBNRAB9AALDH1A1
SCHEMBL3607360 0.84 KMT2A (0.37) DRD2DRD4CRBNRAB9ATSHR
SCHEMBL3595927 0.84 DRD2 (0.37) DRD2DRD4CRBNRAB9ATSHR
SCHEMBL3604103 0.84 CRBN (0.41) DRD2DRD4CRBNRAB9ACHRNA7
SCHEMBL3599654 0.81 DRD2 (0.35) DRD2DRD4CRBNRAB9AALDH1A1
SCHEMBL3590132 0.81 CRBN (0.37) DRD2DRD4CRBNRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 DRD2 530/4885DRD4 795/4885CRBN 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.